Effect of obstructive sleep apnea on right ventricular ejection fraction in patients with hypertrophic obstructive cardiomyopathy

Shengwei Wang1 | Hao Cui2 | Keshan Ji3 | Changwei Ren1 | Hongchang Guo1 | Changsheng Zhu4 | Yongqiang Lai1 | Shuiyun Wang4

1Department of Cardiovascular Surgery Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vascular Diseases, Beijing, China
2Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota, USA
3Department of Special Medical Treatment Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Correspondence
Yongqiang Lai, MD, Department of Cardiovascular Surgery Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vascular Diseases, No.2, Anzhen Road, Chaoyang District, Beijing 100029, China.
Email: yongqianglai@yahoo.com

Shuiyun Wang, MD, Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167, Beilishi Road, Xicheng District, Beijing 100037, China.
Email: wsymd@sina.com

Funding information
Beijing Postdoctoral Research Foundation; National Natural Science Foundation of China, Grant/Award Number: 81570276

Abstract

Background: Obstructive sleep apnea (OSA) is a common disease associated with worse structural and functional impairment of the heart in patients with hypertrophic obstructive cardiomyopathy (HOCM).

Hypothesis: The presence and severity of OSA can decrease the right ventricular ejection fraction (RVEF) in patients with HOCM.

Methods: In total, 151 consecutive patients with a confirmed diagnosis of HOCM at Fuwai Hospital between September 2017 and September 2018 were included. Polysomnography and cardiac magnetic resonance imaging were performed in all patients.

Results: Overall, 84 (55.6%) patients were diagnosed with OSA. The RVEF significantly decreased with the severity of OSA (none, mild, moderate-severe: 46.1 ± 8.2 vs 42.9 ± 7.5 vs 41.4 ± 7.4, P = .009). The apnea-hypopnea index (AHI) was significantly high in patients with RVEF<40% among the different OSA groups (mild, moderate:7.7 ± 2.4 vs 9.6 ± 2.9, P = .03; 24.4 ± 9.0 vs 36.3 ± 18.0, P = .01). In the multiple linear regression model, the right ventricular end-systolic volume (β = −0.28, P < .001), AHI (β = −0.09, P = .02), and oxygen desaturation index (β = −0.11, P = .04) were independently associated with a decrease in RVEF (adjusted R² = 0.347, P < .001). Furthermore, the prevalence of RVEF<40% was high in patients with OSA. Compared with RVEF>40%, RVEF<40% was associated with more symptoms, mainly chest pain, chest distress, NYHA class III or IV, pulmonary hypertension, and moderate or severe mitral regurgitation.

Conclusion: In patients with HOCM, the presence and severity of OSA is independently associated with a lower RVEF. In addition, compared with patients with RVEF>40%, those with RVEF<40% had more symptoms, including chest pain, chest distress, and NYHA class III or IV.

Keywords
hypertrophic obstructive cardiomyopathy, obstructive sleep apnea, right ventricular dysfunction, right ventricular ejection fraction
INTRODUCTION

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease with a prevalence of approximately 1:500 in the general population. About two-thirds of patients with HCM present left ventricular outflow tract (LVOT) obstruction, which has been defined as hypertrophic obstructive cardiomyopathy (HOCM). Obstructive sleep apnea (OSA) is a common sleep disturbance in adults that has been increasingly implicated in the pathogenesis and complications of cardiovascular disease, including HCM. Studies have reported that OSA is common in patients with HCM with a prevalence of 32% to 71%. OSA is independently associated with increased structural and functional cardiac impairment in patients with HCM, including higher NYHA functional classes, and a worse quality of life. Previous studies have revealed that OSA is independently associated with cardiac arrhythmias, enlargement of the left atrial and ascending aorta in patients with HCM. A previous study showed that OSA was associated with right ventricular dysfunction which was reflected by the right ventricular ejection fraction (RVEF), and it could be reversed by OSA treatment. In addition, a previous study reported that in HCM patients, right ventricular dysfunction is common and independently associated with an increased risk of death or transplantation. However, few studies have investigated the relationship between OSA and right ventricular dysfunction in HOCM, and factors associated with right ventricular dysfunction in these patients are unclear. Therefore, in the present study, we aimed to evaluate the factors associated with right ventricular dysfunction reflected by RVEF, and clinical correlates of lower RVEF in patients with HOCM.

METHODS

Study population

This was a prospective observational research study, which included 151 consecutive patients with HOCM who were referred to the Fuwai Hospital (Beijing, China) between September 2017 and September 2018. All patients in the present study underwent cardiac magnetic resonance imaging (MRI) and polysomnography (PSG). The inclusion criteria for patients in this study were the following: (a) age > 18 years; (b) agreement to participate in the study; and (c) diagnosis of HOCM. Patients were excluded if they had >50% of central respiratory events, incomplete sleep recording data, were younger than 18 years, had previous septal reduction therapy (septal myectomy or alcohol septal ablation), or a previous diagnosis of OSA. The diagnostic criteria of HOCM include an unexplained septal hypertrophy with a thickness of >15 mm and a LVOT gradient >50 mm Hg at rest or with provocation according to guidelines. All patients in this study provided informed consent, including use of biomarker analysis and clinical data, prior to enrolment. The study was approved by the Ethics Committee of the Fuwai Hospital (Ethic committee study number: 2019-1213) and was conducted in accordance with the ethical principles stated in the Declaration of Helsinki.

Polysomnography

Standard PSG (Embletta, Embla, UK) was performed in all patients. Respiratory events and data were scored by an experienced scorer. Obstructive apnea was defined as the absence of oro-nasal airflow for at least 10 seconds in the presence of out-of-phase thoracoabdominal effort. Hypopnea was defined as a 50% reduction in oro-nasal airflow for 10 seconds associated with a 4% decrease in oxygen saturation. OSA was classified based on the presence of thoracic efforts. The total recording time was used as the denominator to calculate the apnea-hypopnea index (AHI). The total AHI was calculated and represented the number of events per hour of sleep. The AHI was calculated as the mean number of apneas and hypopneas per hour of sleep. Mild, and moderate to severe OSA were defined as an AHI ≥5 events/h and > 15 events/h, respectively.

Imaging analysis

Echocardiographic evaluation was performed on patients by an experienced physician using an E9 ultrasound system. Diameters of the cardiac chambers were expressed as the maximum value of the anteroposterior diameter in cardiac cycles. The thicknesses of the interventricular septum and ventricular wall were determined during diastole. Aside from the maximum thickness, the representative thickness of the interventricular septal thickness (IVS) was also recorded to indicate overall thickness. The right ventricular diameter was measured in the apical four chamber view. The long axis of the parasternal pulmonary artery was used to measure the pulmonary artery diameter. The LVOT gradient was calculated using a simplified Bernoulli equation. Pulmonary hypertension was defined as pulmonary artery systolic pressure ≥ 35 mm Hg. Measurement of the right ventricular free wall thickness (RVWT) was performed at end-diastole, below the tricuspid annulus at a distance approximating the length of the anterior tricuspid leaflet and RVWT >5 mm was used to define the presence of right ventricular hypertrophy. The measurements of the left ventricular ejection fraction (LVEF) were determined by following the American Society of Echocardiography recommendations. Cardiac MRI was performed using a 1.5 Tesla cardiac magnetic scanner (Magnetom Avanto, Siemens Medical Solutions, Erlangen, Germany). Cine scans in the cardiac short-axis and long-axis views were acquired by applying true imaging with steady-stage precession sequence (TrueFISP). Image analysis was performed using a commercial imaging workstation (Siemens Medical Systems). The LVEF and the indexed left ventricular mass and volume were measured by analyzing a short-axis cine image. Inner and outer myocardial edges were manually delineated. LGE was determined semiautomatically as a percentage of the total myocardium and defined as an intensity >6 SD above the normal myocardium as indicated in previous studies. RVEF was measured by an independent investigator using volumetric measurements on cardiac MRI, and manual tracing of the endocardial borders of the contiguous short-axis slices at end-diastole and end-
systole stages allowed for the calculation of right ventricular end-diastolic volume and right ventricular end-systolic volume.16

2.4 | Statistical analysis

The results in the present study are expressed as mean ± SD, median (interquartile range), or percentage, where appropriate. The $\chi^2$ or Fisher’s exact test was used to compare nominal variables, and differences among the three groups were compared using one-way ANOVA. Before linear regression analysis, Spearman’s rank correlation analysis was performed to select parameters which correlated with RVEF. Furthermore, multivariate linear regression models were used to analyze RVEF. Variables with $P$-value <.10 on univariate analysis were entered into a multivariate analysis. All reported probability values were two-tailed, and a $P$-value <.05 was considered statistically significant. The SPSS version 24.0 software (IBM) and Prism GraphPad 7.0 (GraphPad Software Inc., La Jolla, CA, USA) were used for calculations and illustrations, respectively.

3 | RESULTS

3.1 | Baseline characteristics of the study population

We enrolled 151 patients in the present study (Figure S1). The baseline characteristics of the study population, as well as subgroups stratified according to the severity of OSA, are shown in Table 1. Patients with OSA were older, while a family history of HCM or sudden cardiac death was more common in patients without OSA. Furthermore, compared to patients without OSA, patients with OSA had higher levels of fasting blood glucose, big endothelin, high-sensitivity C-reactive protein (Hs-CRP), and norepinephrine. In addition, patients with OSA had

| TABLE 1 | Baseline characteristics of the study population |
|---------|-----------------------------------------------|
| Variable                                      | No OSA (n = 67) | Mild OSA (n = 45) | Moderate-severe OSA (n = 39) | $P$ value |
| Age, y                                        | 43.7 ± 14.4     | 54.4 ± 11.2$^a$   | 53.2 ± 11.7$^a$               | <.001     |
| Male                                          | 41 (61.2%)      | 26 (57.8%)        | 26 (66.7%)                    | .81       |
| Body mass index, kg/m²                         | 24.2 ± 2.7      | 25.0 ± 3.1        | 25.3 ± 2.7                    | .15       |
| Family history of HCM or SCD                  | 18 (26.9%)      | 5 (11.1%)$^a$     | 4 (10.3%)$^a$                 | .02       |
| NYHA III or IV                                | 49 (73.1%)      | 32 (71.1%)        | 24 (61.5%)                    | .44       |
| Fasting blood glucose, mmol/L                 | 4.4 ± 0.7       | 4.8 ± 0.8$^a$     | 5.2 ± 1.7$^{ab}$              | <.001     |
| Big endothelin, pmol/L                        | 0.33 ± 0.13     | 0.50 ± 0.30$^a$   | 0.57 ± 0.37$^a$               | <.001     |
| Hs-CRP, mg/L                                  | 1.42 (1.06-1.85)| 1.84 (0.60-2.79)  | 2.01 (0.60-3.65)$^{ab}$       | .02       |
| BNP, pg/mL                                     | 1400.0 (581.9-2116.0) | 1189.0 (521.8-2707.0) | 1351.0 (495.2-1919.0) | .74       |
| Norepinephrine, ng/ml                          | 0.28 ± 0.05     | 0.31 ± 0.08$^a$   | 0.35 ± 0.11$^{ab}$            | <.001     |
| Concomitant disease                            |                 |                   |                                |           |
| Hypertension                                   | 7 (10.4%)       | 11 (24.4%)        | 8 (20.5%)                     | .13       |
| Hyperlipidemia                                 | 15 (22.4%)      | 11 (24.4%)        | 12 (30.8%)                    | .63       |
| Diabetes mellitus                              | 3 (4.5%)        | 3 (6.7%)          | 3 (7.7%)                      | .77       |
| Clinical presentation                          |                 |                   |                                |           |
| Chest pain                                     | 17 (25.4%)      | 8 (17.8%)         | 23 (59.0%)                    | .87       |
| Amaurosis                                      | 10 (15.2%)      | 7 (15.6%)         | 5 (12.8%)                     | .93       |
| History of syncope                             | 8 (11.9%)       | 7 (15.6%)         | 13 (33.3%)$^{ab}$             | .02       |
| Chest distress                                 | 37 (55.2%)      | 24 (53.3%)        | 23 (59.0%)                    | .87       |
| Dizziness                                      | 11 (16.4%)      | 8 (17.8%)         | 4 (10.5%)                     | .62       |
| Palpitation                                    | 8 (11.9%)       | 4 (8.9%)          | 9 (23.1%)                     | .14       |
| Atrial fibrillation                            | 6 (9.0%)        | 9 (20.0%)$^a$     | 10 (25.6%)$^{ab}$             | .02       |
| Medical therapy                                |                 |                   |                                |           |
| Beta-blockers                                  | 44 (65.7%)      | 34 (75.6%)        | 26 (66.7%)                    | .51       |
| Calcium-channel blockers                      | 10 (14.9%)      | 8 (17.8%)         | 3 (7.7%)                      | .39       |

Abbreviations: BNP, brain natriuretic peptide; HCM, hypertrophic cardiomyopathy; Hs-CRP, high-sensitivity C-reactive protein; NYHA, New York Heart Association; OSA, obstructive sleep apnea; SCD, sudden cardiac death.

$^aP < .05$, Mild OSA or moderate-severe OSA vs no OSA.

$^bP < .05$, Mild OSA vs moderate-severe OSA.
a higher incidence of syncope (11.9% vs 15.6% vs 33.3%, \( P = .02 \)), and atrial fibrillation (9.0% vs 20.0% vs 25.6%, \( P = .02 \)). There were no differences in any of the other parameters detailed in Table 1.

### 3.2 Imaging parameters of the study population

The imaging parameters of the study population stratified according to the severity of OSA are shown in Table 2. As also shown in Table 2, the echocardiographic indices, including the prevalence of pulmonary hypertension, right ventricular hypertrophy, moderate or severe mitral regurgitation, left atrial diameter, left ventricular end-diastolic dimension, pulmonary artery diameter, right ventricular diameter, and right ventricular wall thickness, were significantly increased with the severity of OSA. In addition, we found that the value of the indexed left ventricular mass, indexed left ventricular volume, and LGE% were also increased with the severity of OSA. Most importantly, the RVEF (46.1 ± 8.2 vs 42.9 ± 7.5 vs 41.4 ± 7.4, \( P = .009 \)) was decreased with the severity of OSA. The prevalence of RVEF<40% was also significantly higher in patients with OSA. In addition, the AHI value was significantly higher in patients with RVEF<40% compared to the different OSA groups (Figure 1).

### 3.3 PSG parameters of the study population

The PSG parameters of the study population are summarized in Table 3. Compared with patients without OSA, almost all PSG parameters, including the AHI, OSA index, oxygen desaturation index (ODI), and time ratio of SpO2 < 90% were significantly higher in patients with OSA. However, sleep efficiency, and REM sleep were significantly lower in patients with OSA. Importantly, there was no difference in the total sleep time among the three groups. Detailed information is shown in Table 3.

### 3.4 Factors associated with RVEF and the effect of lower RVEF on HOCM patients

Multiple variables, including baseline characteristics, imaging parameters, and PSG parameters, were included in a correlation analysis to further identify the determinants of the decrease of RVEF in HOCM patients (Table 4). In the multiple linear regression analysis, right ventricular end-diastolic volume (\( \beta = -0.28, P < .001 \)), AHI (\( \beta = -0.09, P = .02 \)), and ODI (\( \beta = -0.11, P = .04 \)) were independently associated with a decrease in RVEF (adjusted \( R^2 = 0.347, P < .001 \)), when

### Table 2 Imaging parameters of the study population

| Variable                        | No OSA (n = 67) | Mild OSA (n = 45) | Moderate-severe OSA (n = 39) | P value |
|---------------------------------|-----------------|-------------------|-----------------------------|---------|
| Echocardiographic indices       |                 |                   |                             |         |
| LVEF, %                         | 67.9 ± 6.0      | 67.8 ± 5.7        | 68.1 ± 6.4                  | .97     |
| Left atrial diameter, mm        | 42.9 ± 6.7      | 44.9 ± 5.9        | 46.0 ± 7.7                  | .06     |
| LVEDD, mm                       | 40.5 ± 3.9      | 42.6 ± 4.6        | 44.8 ± 4.4\(^{ab}\)         | <.001   |
| IVST, mm                        | 21.6 ± 5.6      | 20.8 ± 4.1        | 20.4 ± 2.6                  | .45     |
| RVH                             | 33 (49.3%)      | 25 (55.6%)        | 29 (74.4%)\(^{ab}\)         | .02     |
| RVWT, mm                        | 5.9 ± 1.5       | 6.3 ± 1.7         | 7.2 ± 1.6\(^{ab}\)          | .001    |
| Pulmonary artery diameter, mm   | 23.0 ± 2.9      | 24.5 ± 4.0        | 24.8 ± 2.6\(^a\)            | .01     |
| Right ventricular diameter, mm  | 21.1 ± 2.5      | 21.9 ± 3.0        | 22.6 ± 3.9\(^a\)            | .04     |
| LVOT gradient, mm Hg            | 69.7 ± 24.4     | 72.5 ± 21.3       | 75.2 ± 25.6                 | .51     |
| Pulmonary hypertension          | 2 (3.0%)        | 5 (11.1%)\(^a\)  | 7 (17.9%)\(^{ab}\)          | .03     |
| Moderate or severe MR           | 25 (37.3%)      | 21 (46.7%)        | 27 (69.2%)\(^{ab}\)         | .006    |
| Cardiac magnetic resonance imaging |                |                   |                             |         |
| Indexed LV mass, g/m\(^2\)     | 93.9 ± 27.1     | 90.5 ± 23.9       | 107.0 ± 43.7\(^{ab}\)       | .04     |
| Indexed LV volume, ml/m\(^2\)  | 88.6 ± 28.9     | 86.5 ± 23.0       | 101.9 ± 41.6\(^a\)          | .05     |
| LGE, % of LV mass               | 6.1 (3.4-10.0)  | 6.8 (3.6-12.9)    | 10.9 (8.3-15.5)\(^{ab}\)    | .01     |
| RVEDV, mL                       | 78.6 ± 19.2     | 79.2 ± 27.2       | 80.4 ± 18.2                 | .92     |
| RVESV, mL                       | 42.5 ± 13.8     | 45.8 ± 21.3       | 46.9 ± 11.9                 | .35     |
| RVEF, %                         | 46.1 ± 8.2\(^a\)| 42.9 ± 7.5        | 41.4 ± 7.4                  | .009    |
| RVEF<40%                        | 13 (19.4%)      | 14 (31.1%)\(^a\) | 17 (43.6%)\(^{ab}\)         | .008    |

Abbreviations: IVST, interventricular septal thickness; LGE, late gadolinium enhancement; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; OSA, obstructive sleep apnea; RVEDV, right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; RVESV, right ventricular end-systolic volume; RVH, right ventricular hypertrophy; RVWT, right ventricular wall thickness.

\(^aP<.05,\) Mild OSA or moderate-severe OSA vs no OSA.

\(^bP<.05,\) Mild OSA vs moderate-severe OSA.
adjusted for age, sex, body mass index (BMI), and the other parameters that associated with a decrease of RVEF in the spearman analysis.

The baseline characteristics according to the subgroup of RVEF are shown in Table S1. We found that HOCM patients with RVEF <40% had more symptoms, including chest pain, chest distress, NYHA class III or IV, and had a higher prevalence of pulmonary hypertension, and moderate or severe mitral regurgitation. In addition, the left ventricular end-diastolic diameter, IVS, right ventricular diameter, right ventricular end-diastolic volume, and right ventricular wall thickness were also significantly increased in patients with RVEF <40%.

Furthermore, compared with a RVEF ≥40%, the prevalence of mild and moderate-severe OSA was significantly higher in patients with a RVEF<40% (Figure S2).

### 4 | DISCUSSION

To our knowledge, this is the first study to systematically investigate the relationship between OSA and RVEF in patients with HOCM. The main findings of the study were as follows: First, RVEF significantly...
OSA may affect HOCM through many mechanisms, including activation of the sympathetic nervous system, an increase in insulin resistance, increased myocardial wall stress, and impairment of vascular endothelial function. The effect of OSA on the level of fasting blood glucose, endothelin, norepinephrine, and hs-CRP have been well characterized in our previous studies. In addition, insulin resistance may increase the prevalence of atrial fibrillation in HOCM patients through its association with increased left atrial size or left ventricular diastolic impairment. Furthermore, our previous study also found that type 2 diabetes mellitus which is closely associated with insulin resistance is associated with a higher sudden cardiac death rate in a matched cohort with HOCM who underwent septal myectomy. However, there is a paucity of information on the relationship between OSA and right ventricular function in patients with HOCM. A previous study showed that right ventricular dysfunction reflected by RVEF is common in OSA, and it is reversible with the treatment of OSA. Another study published recently also showed that nocturnal hypoxemia is associated with right ventricle diastolic function in OSA. Furthermore, OSA is also an independent risk factor for subclinical right ventricular dysfunction in children. In our study, we found that the diameter of the pulmonary artery and right ventricle significantly increased with the severity of OSA, which might underly the right ventricular dysfunction. In addition, previous studies have reported that a RVEF <40% is a marker of increased risk of death and hospitalization, and a RVEF <20% is an independent risk factor for death and heart failure hospitalization in heart failure patients. Importantly, a recent study reported that more than half of HCM patients had right ventricular diastolic and systolic dysfunction, and right ventricular function was associated with exercise capacity. Furthermore, right ventricular hypertrophy correlated with increased calculated sudden cardiac death risk score and independently related to the presence of ventricular arrhythmias. In the present study, we found that RVEF <40% was more common in patients with OSA, and the value of RVEF significantly decreased with the severity of OSA. After adjustment for age, sex, and other relevant variables identified by the Spearman’s correlation analysis, the AHI and ODI were also independently associated with a decrease in RVEF. These results suggest that OSA is an independent risk factor for the decrease in RVEF; however, the exact mechanism is unclear. In addition, right ventricular wall thickness increased with the severity of OSA, and right ventricular hypertrophy was more common in patients with OSA. The findings of the present study suggest that the presence and severity of OSA might cause impairment in right ventricular function in HOCM patients.

Previous studies have revealed that RVEF is influenced by right ventricular contractility, right ventricular end-diastolic pressure, and pulmonary vascular pressure. Experimental studies on mice have showed that intermittent hypoxia, which simulates the effect of repeated nocturnal apneas, can induce repeated instantaneous episodes of right ventricular overload through hypoxic vasoconstriction of pulmonary microcirculation. With time, this could lead to the remodeling of the pulmonary artery and chronic pulmonary hypertension. In the present study, the prevalence of pulmonary hypertension was significantly higher in patients with OSA or RVEF <40%, which is consistent with previous studies. In addition, the prevalence of moderate or severe mitral regurgitation was also higher in patients with OSA. Mitral regurgitation, which influences pulmonary venous pressure, may be a determinant of right ventricular function, and several studies have suggested that mitral regurgitation severity is associated with a decrease in RVEF. Furthermore, in our study, septal thickness was significantly higher in patients with a RVEF <40%, which is consistent with previous studies indicating

| Variable                | Univariate rs | P       | Multivariate adjusted R² = 0.347 β | P      |
|-------------------------|---------------|---------|-----------------------------------|--------|
| Age                     | −0.07         | .39     |                                   |        |
| Sex                     | 0.16          | .06     |                                   |        |
| Body mass index         | 0.05          | .51     |                                   |        |
| LVEDD                   | −0.17         | .04     |                                   |        |
| Pulmonary artery diameter | −0.14       | 0.09    |                                   |        |
| Right ventricular diameter | −0.12       | .05     |                                   |        |
| RVESV                   | −0.50         | <.001   | −0.28                             | <.001  |
| RVWT                    | −0.176        | .03     |                                   |        |
| LGE                     | −0.25         | .002    |                                   |        |
| Apnea hypoxia index     | −0.27         | .001    | −0.16                             | .023   |

Abbreviations: LGE, late gadolinium enhancement; LVEDD, left ventricular end-diastolic dimension; RVEF, right ventricular ejection fraction; RVESV, right ventricular end-diastolic volume; RVWT, right ventricular wall thickness.
RVEF may also be impaired because of ventricular interdependence associated with septal dysfunction and limited pericardial flexibility.29,30

Another finding in our study was that a RVEF<40% was associated with symptoms, including chest pain, chest distress, and NYHA class III or IV in patients with HOCM. This is consistent with a previous study that found that right ventricular dysfunction helped to predict severe symptomatic HCM with high sensitivity and specificity.31 In addition, right ventricular dysfunction was independently associated with reduced exercise capacity in patients with HCM.21 In the present study, the presence and severity of OSA were independent risk factors for a decrease in RVEF, which affected the clinical manifestation of HCM patients.

Impairment of right ventricular function is associated with adverse clinical outcomes in cardiovascular disease, including chronic heart failure, right ventricular myocardial infarction, and ischemic and nonischemic cardiomyopathy.30 In addition, patients with severe untreated OSA had a higher incidence of fatal and nonfatal cardiovascular events than those without OSA, but the exact mechanism is unknown. In HOCM patients with OSA, a lower RVEF caused by OSA might be associated with a poor clinical outcome for these patients. Importantly, previous studies have reported that treatment of OSA can reverse right ventricular function, and may lead to a marked improvement in symptoms and reduce the LVOT gradient which would abrogate the need for septal reduction in patients with HOCM and OSA.8,32 Therefore, we believe that early diagnosis and timely treatment for these patients may alleviate the symptoms caused by lower RVEF and improve the quality of life for these patients.

5 | LIMITATIONS

There are some limitations in our study. First, sleep was only studied for one night in all the patients. In fact, the parameters of OSA showed a considerable night-to-night variability; thus, a single-night diagnostic sleep study is prone to mis-categorize the severity of OSA. Second, the present study was carried out in a single research center and the number of patients included was small. A multicenter study with a larger population of HOCM patients is needed to confirm our results, and a multicenter collaborative clinical trial studying the treatment effects of OSA is necessary. Finally, due to the cross-sectional nature of the present study, it was not possible to conclude that OSA and a lower RVEF were independently associated with future adverse cardiovascular complications in patients with HOCM.

6 | CONCLUSIONS

In patients with HOCM, the presence and severity of OSA was independently associated with a lower RVEF. In addition, patients with a RVEF <40% had symptoms including chest pain, chest distress, NYHA class III or IV, a higher prevalence of pulmonary hypertension, and moderate or severe mitral regurgitation. In addition, the left ventricular end-diastolic diameter was also significantly increased in patients with a RVEF <40%, which is a marker for disease severity in HOCM. Further studies are needed to investigate the impact of OSA and RVEF on future cardiovascular complications as well as the safety and efficacy of OSA treatment in these patients.

CONFLICT OF INTEREST
The authors declare no potential conflict of interest.

ORCID
Shengwei Wang https://orcid.org/0000-0003-3928-7945

REFERENCES
1. Gersh BJ, Maron BJ, Bonow RO. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Thorac Cardiovasc Surg. 2011;142(6):e153-e203.
2. Shamussaaman AS, Somers VK, Knilans TK, Ackerman MJ, Wang Y, Amin RS. Obstructive sleep apnea in patients with congenital long QT syndrome: implications for increased risk of sudden cardiac death. Sleep. 2015;38(7):1113-1119.
3. Nerbass FB, Pedrosa RP, Danzi-Soares NJ, Drager LF, Arteaga-Fernandez E, Lorenzi-Filho G. Obstructive sleep apnea and hypertrophic cardiomyopathy: a common and potential harmful combination. Sleep Med Rev. 2013;17(2):201-206.
4. Venkataraman S, Karim S, Rajendran A, Chahal CAA, Somers VK. Sleep disordered breathing in hypertrophic cardiomyopathy—current state and future directions. Journal of Clinical Medicine. 2020;9(4):901. http://dx.doi.org/10.3390/jcm9040901.
5. Koncny T, Brady PA, Orban M, et al. Interactions between sleep disordered breathing and atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardio. 2010;105(11):1597-1602.
6. Pedrosa RP, Drager LF, Genta PR, et al. Obstructive sleep apnea is common and independently associated with atrial fibrillation in patients with hypertrophic cardiomyopathy. Chest. 2010;137(5):1078-1084.
7. Wang S, Cui H, Song C, et al. Obstructive sleep apnea is associated with nonsustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm. 2019;16(5):694-701.
8. Nahmias J, Lao R, Karetzky M. Right ventricular dysfunction in obstructive sleep apnoea: reversal with nasal continuous positive airway pressure. Eur Respir J. 1996;9(5):945-951.
9. Finocchiaro G, Knowles JW, Pavlovic A, et al. Prevalence and clinical correlates of right ventricular dysfunction in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2014;113(2):361-367.
10. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-2779.
11. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999;22(5):667-689.
12. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16(3):233-270.
13. Cardim N, Gallerisi M, Edvardsen T, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic...
cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015;16(3):280.

14. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-1463.

15. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5(4):370-377.

16. Speiser U, Hirschberger M, Pilz G, et al. Tricuspid annular plane systolic excursion assessed using MRI for semi-quantification of right ventricular ejection fraction. Br J Radiol. 2012;85(1017):e716-e721.

17. Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet. 2009;373(9657):82-93.

18. Wang S, Cui H, Zhu C, et al. Obstructive sleep apnea causes impairment of the carotid artery in patients with hypertrophic obstructive cardiomyopathy. Respir Med. 2019;150:107-112.

19. Scotti C, Porta R, Olivares A, Comini L, Cinelli A, Scalvini S, Vitacca M. Nocturnal hypoxemia impacts right ventricle diastolic function in obstructive sleep apnea: a retrospective observational Study. Journal of Clinical Medicine. 2020;9(1):162. http://dx.doi.org/10.3390/jcm9010162.

20. Meyer P, Filippatos GS, Ahmed MI, et al. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation. 2010;121(2):252-258.

21. Wu XP, Li YD, Wang YD, et al. Impaired right ventricular mechanics at rest and during exercise are associated with exercise capacity in patients with hypertrophic cardiomyopathy. J Am Heart Assoc. 2019;8(5):e011269.

22. Rosca M, Calin A, Beladan CC, et al. Right ventricular remodeling, its correlates, and its clinical impact in hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2015;28(11):1329-1338.

23. Bleasdale RA, Frenneaux MP. Prognostic importance of right ventricular dysfunction. Heart. 2002;88(4):323-324.

24. Sabe MA, Sabe SA, Kusunose K, Flamm SD, Griffin BP, Kwon DH. Predictors and prognostic significance of right ventricular ejection fraction in patients with ischemic cardiomyopathy. Circulation. 2016;134(9):656-665.

25. Campen MJ, Shimoda LA, O’Donnell CP. Acute and chronic cardiovascular effects of intermittent hypoxia in C57BL/6J mice. J Appl Physiol (1985). 2005;99(5):2028-2035.

26. KA F. Selected Contribution: Pulmonary hypertension in mice following intermittent hypoxia. J Appl Physiol (1985)2001;90(6):2502–2507.

27. Tourneau TL, Deswarthe G, Lamblin N, et al. Right ventricular systolic function in organic mitral regurgitation: impact of biventricular impairment. Circulation. 2013;127(15):1597–1608.

28. Shields JP, Watson P, Mielke CH. The right ventricle in mitral regurgitation: evaluation by electron beam tomography. J Heart Valve Dis. 1995;4(5):490-494. discussion 494-495.

29. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008;117(13):1717-1731.

30. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation. 2008;117(11):1436-1448.

31. Zhang S, Yang ZG, Sun JY, et al. Assessing right ventricular function in patients with hypertrophic cardiomyopathy with cardiac MRI: correlation with the New York heart function assessment (NYHA) classification. PLoS One. 2014;9(9):e104312.

32. Sengupta PP, Sorajja D, Eleid MF, et al. Hypertrophic obstructive cardiomyopathy and sleep-disordered breathing: an unfavorable combination. Nat Clin Pract Cardiovasc Med. 2009;6(1):14-15.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Wang S, Cui H, Ji K, et al. Effect of obstructive sleep apnea on right ventricular ejection fraction in patients with hypertrophic obstructive cardiomyopathy. Clin Cardiol. 2020;43:1186–1193. https://doi.org/10.1002/clc.23429